AstraZeneca weighing bid for Mereo BioPharma: Report

June 17, 2022

Today 3:44 AM ET (MarketWatch)

AstraZeneca (AZN.LN) is considering a bid for London-based, U.S.-listed biotech Mereo BioPharma (MREO), The Times reported without attribution. AstraZeneca already is a partner of Mereo, and the report said it may face competition from another of the cancer and rare disease specialist’s partners, which include Novartis (NOVN.EB), OncXerna and Ultragenyx (RARE).

https://www.marketwatch.com/story/astrazeneca-weighing-bid-for-mereo-biopharma-report-2022-06-17

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.